Clinical Trials Logo

Chronic Liver Disease clinical trials

View clinical trials related to Chronic Liver Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04734496 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Evaluation of the Mechanisms of Sarcopenia in Chronic Inflammatory Disease: Protocol for a Prospective Cohort Study

Start date: January 1, 2019
Phase:
Study type: Observational

Prospective, observational study to assess sarcopenia across three chronic inflammatory diseases: chronic liver disease, Inflammatory Bowel Disease, Rheumatoid Arthritis both before and after therapeutic intervention (standard of care treatment i.e. nutrition/exercise; biologic for IBD etc).

NCT ID: NCT01246388 Active, not recruiting - Clinical trials for Chronic Liver Disease

Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy

Start date: May 2010
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate non-invasive parameters for staging and grading of chronic hepatopathy in comparison to liver biopsy.

NCT ID: NCT01205074 Active, not recruiting - Healthy Subjects Clinical Trials

¹³C-Methacetin Breath Test (MBT) Methodology Study

Start date: September 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Several factors will be tested to see if they have an influence on the methacetin breath test results. Each one of the factors has been raised as a possible source of distortion of the MBT result. I. Variability between same tests on same subject MBT. Repeatability will be tested in both healthy individuals and patients with chronic liver disease. II. COPD - Chronic obstructive pulmonary disease is a leading cause of death worldwide, and can potentially have an effect on the MBT since the breath test is based on CO2 production and these subjects may have abnormal CO2 production. III. Smoking- 13C Methacetin is metabolized by healthy hepatocytes reflecting hepatic microsomal function of CYP1A2, and smoking may cause induction of CYP1A2. Furthermore, internal preliminary data has shown signs that there is an influence of smoking on the MBT ranges. IV. Age- Empirical data on several hundred subjects with chronic liver disease has shown that age is a significant factor in determining the probability of disease severity and preliminary data in normal subjects have shown changes in MBT with age.. Therefore, the effect of age has to be elucidated in an orderly fashion. V. CYP450 1A2 Inhibitors- Several drugs and food items inhibit CYP450 1A2 and may affect the MBT. VI. Alcohol - Alcohol ingestion leads to induction of hepatic CYP and at a later stage to inhibition due to liver damage. Acute alcohol ingestion may therefore effect MBT results. VII. Beta-blockers - beta blocker are affecting portal hypertension and may affect hepatic blood flow and thereby the outcome of the methacetin breath test.